Modulated Imaging (dba Modulim) was recently highlighted by National Institute of Aging (NIA) as a showcase company. Modulim successfully completed a Phase 2 Small Business Innovation Research (SBIR) program with the National Institute of Aging (NIA) to conduct R&D and build a system that brings Spatial Frequency Domain Imaging (SFDI) to the point-of-care for chronic wound management. Many of these advances were incorporated into the FDA-cleared Clarifi® Imaging System.
An estimated 6.5M people in the US suffer from chronic wounds (i.e., diabetic foot ulcers and pressure ulcers). The incidence of chronic wounds continues to increase due to an aging population and an increase in diabetes and obesity. Quantification and imaging of tissue oxygenation and perfusion is seen as a method to identity, manage, and possibly prevent chronic wounds. The Clarifi Imaging system was developed to measure oxygenation in patients with potential compromised circulation in a non-contact manner over large areas.
The NIA, one of the 27 Institutes and Centers of the National Institute of Health (NIH), leads a broad scientific effort to understand the nature of aging and to extend the healthy, active years of life. As an NIA showcase company, Modulim was selected to participate in the Innovator’s Pitch Challenge with other showcase companies at the January 2021 Redefining Early-Stage Investment (RESI) conference.
Modulim is a privately held medical device company founded by the inventors of SFDI at the University of California Irvine with a team dedicated to delivering powerful healthcare solutions that elevate and standardize health care delivery, while improving patient outcomes. Its mission is to deliver transformative optical solutions that help people live healthier, longer lives. Clarifi®, powered by Spatial Frequency Domain Imaging (SFDI) technology, identifies compromised circulation at the point of care through non-contact rapid microvascular assessment of tissue. Clinicians and healthcare systems are empowered by SFDI images to make proactive, data-driven decisions in a multidisciplinary care setting, to reduce lower-limb complications caused by diabetes and peripheral arterial disease. Clarifi Imaging System is an FDA cleared and CE Marked product. Modulim is backed by Pangaea Ventures, Fresenius Medical Care Ventures, Grey Sky Venture Partners, Mitsubishi Capital, Hamamatsu Photonics, The Cove Fund at UCI Applied Innovation, and Fouse KK. Clarifi is a registered trademark of Modulated Imaging (dba Modulim).
VP Sales and Marketing
Source of chronic wound data: